华润双鹤药业2025年度报告摘要：业绩、业务布局、行业趋势与创新发展分析

华润双鹤药业股份有限公司2025年度报告深度解析

摘要与重要提示

华润双鹤药业股份有限公司（600062）发布2025年度报告摘要，董事会及高管团队全体出席会议，毕马威华振会计师事务所出具了标准无保留意见审计报告。公司拟以股权登记日登记的总股本为基数分配利润，每10股派发现金红利3.79元（含税），年度现金分红总额达4.97亿元，占合并口径归属于上市公司股东净利润的30.21%。公司利润分配方案若总股本发生变化，将调整分配总额并另行公告。这一分红比例和政策，显示公司持续回馈股东，对投资者来说具有价格敏感性。

行业与政策环境

医药行业企稳回升：2025年医药制造业实现营业收入2.49万亿元，同比下降1.2%；利润总额3490亿元，同比增长2.7%。行业利润增速下半年转正，韧性强，医保基金收入支出平稳，基金结余充足，为创新药准入及支付改革提供保障。
政策体系持续完善：创新药全链条支持体系落地，医保局推动“商业健康保险创新药品目录”，DRG/DIP支付方式改革保障创新药临床使用，显著提升创新药可及性。仿制药集采规则优化，防止非理性低价竞争，续约谈判常态化推进。
研发创新爆发：高技术制造业利润增13.3%，基因工程药物和疫苗制造利润分别增长72.7%和37.1%。药监局强调临床试验监管和仿制药质量提升，临床试验审批效率提升，创新药准入周期缩短。
生产与营销端变革：药品追溯码全链条管理，数智化转型加速，绿色制造要求提升，委托生产监管趋严。药品集采周期延长至3年，价格治理全国协同，医疗反腐全链条治理，基层市场扩容，线上市场快速增长。
国际化战略：中国-东盟医药集采平台建成，支持药械“走出去”，显著降低中国药企开拓东南亚市场门槛和成本。

公司主营业务与经营情况

慢病业务：重点聚焦降压、降糖、脑血管、降脂领域，形成慢病药物产品群。核心产品受省采和渠道治理影响收入下滑，但部分产品如缬沙坦氢氯噻嗪片、硝苯地平缓释片等集采续约后收入增长。慢病业务收入占比30%，带量采购影响最大，公司积极优化资源配置与营销模式转型，推进数字化营销。
专科业务：布局儿科、肾科、精神/神经、肿瘤、女性健康、抗凝等领域。肾科用药收入同比增长17%，肿瘤领域收入同比增长45%，女性健康产品收入增长8%，抗病毒药溴夫定收入增长超350%。专科业务收入占比28%，同比增长3.2个百分点。
输液业务：全国布局，提升产线自动化水平。基础输液市场价格下滑，公司增强产品结构调整，强化销售端协同，维持行业前三市场份额。输液业务收入25.3亿元。
原料药业务：涵盖化学合成、生化提取、生物发酵领域。合成生物赋能，成本控制，结构优化，原料药销量实现双位数增长。原料药业务收入12.6亿元。

财务数据与股东情况

财务表现：2025年营业收入110.01亿元，同比下降1.88%；利润总额19.11亿元，同比增长2.36%；归属净利润16.47亿元，同比增长1.18%；扣除非经常性损益的净利润同比增长9.5%。经营活动现金流净额同比下降18.39%。加权平均净资产收益率14.86%，基本每股收益1.5949元。
分红政策：年度分红比例高，现金分红总额4.97亿元，回报股东力度显著，对股价有积极影响。
股东结构：报告期末普通股股东总数55722，前十大股东中北京医药集团持股60.24%，公司未有资料显示前十名股东是否存在关联关系或一致行动人关系。

重大经营事项与未来展望

业绩驱动：慢病、专科、输液、原料药业务均有亮点，部分新药收入增长显著，如香雷糖足膏收入同比增长超470%，肿瘤、肾科、抗病毒领域持续拓展，带量采购影响下，产品结构调整与低成本战略推进。
研发创新：创新药管线储备15个重点项目，多个创新药获批或进入临床阶段，仿制药及原料药获批33个，申报32个，国采中选产品71个。技术平台建设推进，独家产品复产贡献收入超5亿元。
合成生物布局：合成生物研究院建成7大技术平台，20余在研项目，高温尼龙前体项目入选工信部标志性产品。神舟生物产能与效益双提升，成立合成生物产业基金。
外延发展：收购河南中帅53.28%股权，进入精麻产品领域，拓展儿童ADHD领域，获得一类精神药品资质。引进5个新产品，覆盖肿瘤、儿童神经/精神、降糖、眼科等领域。
卓越运营：仿制药“研产销”能力提升，集采产品研发效率加快。营销模式转型，探索商销、零售、电商多模式整合，OTC平台建设加快。生产资源配置与产业化升级，安徽双鹤健康产业园搬迁一期动工，数字化覆盖率达86%。
退市风险：公司不存在退市风险警示或终止上市情形。

投资者需关注的价格敏感事项

高比例现金分红及持续回馈股东政策，提升公司吸引力。
创新药、仿制药、原料药多项管线进展，未来增长潜力巨大。
合成生物布局及产业基金设立，为公司第二增长曲线提供支撑。
重大收购及新产品引进，拓展新领域并丰富产品线。
持续推进低成本战略、数字化转型、卓越运营提升盈利能力。
公司不存在退市风险，经营稳健。

免责声明

本文仅为信息披露和投资参考，不构成任何投资建议。投资者应根据自身情况及专业意见做出决策，公司业绩及未来表现受行业政策、市场环境等多因素影响，投资需谨慎。

China Resources Double Crane Pharmaceutical Co., Ltd. 2025 Annual Report Deep Dive (English)

Summary & Key Highlights

China Resources Double Crane (600062) released its 2025 annual report summary. The board and management team fully attended the meeting, and KPMG Huazhen issued a standard unqualified audit report. The company plans to distribute cash dividends of RMB 3.79 (tax-included) per 10 shares based on the total equity registered on the equity distribution record date. Total annual cash dividend is RMB 497 million, accounting for 30.21% of consolidated net profit attributable to shareholders. Any change in total equity will adjust the distribution amount. This high dividend ratio is price sensitive and shows continued shareholder returns.

Industry & Policy Environment

Pharmaceutical Industry Recovery: In 2025, pharmaceutical manufacturing revenue reached RMB 2.49 trillion (-1.2% YoY), profit RMB 349 billion (+2.7% YoY). Industry profits turned positive in H2, displaying resilience. Medical insurance funds remained stable, with sufficient surpluses supporting innovative drug access and payment reform.
Policy Improvements: All-chain support for innovative drugs, commercial health insurance innovative drug directory, DRG/DIP payment reforms, enhancing drug accessibility. Generic drug procurement rules optimized to avoid irrational competition; renewal negotiations normalized.
R&D Innovation Boom: High-tech manufacturing profit up 13.3%, gene engineering drugs +72.7%, vaccines +37.1%. Regulatory efficiency improved, faster innovative drug access.
Production & Marketing Changes: Full-chain drug traceability, accelerated digital transformation, stricter green manufacturing requirements, tighter contract manufacturing regulation. National collaborative drug price governance, medical anti-corruption, expanded grassroots and online markets.
Internationalization: China-ASEAN pharma procurement platform launched, lowering barriers and costs for China pharma to enter Southeast Asia.

Main Businesses & Operations

Chronic Disease Business: Focus on hypertension, diabetes, cerebrovascular, lipid-lowering. Core products affected by provincial procurement, but some saw growth post-renewal. Chronic disease business accounts for 30% of revenue, most impacted by bulk procurement. Digital marketing and channel optimization underway.
Specialty Business: Coverage includes pediatrics, nephrology, neuro/psychiatric, oncology, women’s health, anticoagulants. Nephrology up 17% YoY, oncology up 45% YoY, women’s health up 8%, antiviral up 350%. Specialty business accounts for 28% of revenue, up 3.2ppt YoY.
Infusion Business: Nationwide manufacturing base, automation upgrades. Declining prices in basic infusion segment, but company adjusts product structure and maintains top three market share. Infusion revenue RMB 2.53 billion.
API Business: Covers chemical synthesis, biochemical extraction, fermentation. Synthetic biology enables cost reduction, sales up double digits. API business revenue RMB 1.26 billion.

Financial Data & Shareholder Structure

Performance: 2025 revenue RMB 11.0 billion (-1.88% YoY), profit RMB 1.91 billion (+2.36% YoY), net profit RMB 1.65 billion (+1.18% YoY), non-recurring net profit +9.5% YoY. Operating cash flow down 18.39%. ROE 14.86%, basic EPS RMB 1.5949.
Dividend Policy: High payout ratio, annual cash dividend RMB 497 million, strong shareholder return.
Shareholder Structure: 55,722 ordinary shareholders at period end, Beijing Pharmaceutical Group holds 60.24%. No evidence of related party or concerted action among top ten shareholders.

Major Business Events & Outlook

Growth Drivers: New drugs like Xianglei diabetic foot cream up 470% YoY, steady expansion in oncology, nephrology, antiviral. Product structure adjustment and low-cost strategies under bulk procurement pressure.
R&D Innovation: 15 key innovative drug projects in pipeline, several approvals/clinical entries, 33 generic/API approvals, 71 products selected for national procurement. Technical platform buildout, unique product resumption contributed over RMB 500 million in revenue.
Synthetic Biology: 7 tech platforms, 20+ projects, high-temperature nylon precursor project selected as MIIT flagship. Shenzhou Biotech production and profit up, synthetic biology fund established.
External Growth: Acquired 53.28% of Henan Zhongshuai, entered psychotropic drug sector, expanded ADHD market, 5 new products introduced covering oncology, pediatric neuro/psychiatric, diabetes, ophthalmology.
Excellence in Operations: Enhanced “R&D-Production-Sales” integration, efficient generic drug R&D for procurement, multi-model marketing transformation, OTC platform buildout accelerated. Production resource upgrades, digitalization rate at 86%.
No delisting risk: Company is stable, no risk warning or termination of listing.

Price Sensitive Issues for Investors

High cash dividend policy, strong shareholder returns.
Innovative drug pipeline progress, future growth potential.
Synthetic biology layout and fund establishment for second growth curve.
Major acquisitions and new product launches, expanding business scope.
Ongoing cost reduction, digital transformation, operational excellence enhancing profitability.
No delisting risk, solid operations.

Disclaimer

This article is for information disclosure and investment reference only and does not constitute investment advice. Investors should make decisions based on their own circumstances and professional advice. Company performance and future prospects are affected by various factors including industry policy and market environment. Please invest prudently.